Want to join the conversation?
$EOG 2Q15 PR: Net operating revenues were $2.47Bil vs. $4.2Bil in 2Q14. Net income was $5.3MM, or $0.01 per share vs. $706.4MM, or $1.29 per share, in 2Q14. In 2Q15, EOG continued to improve well productivity and reduce completed well costs and operating costs.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.